Cancer Target: Mesothelin

thomas.m

Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment.

In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis of mesothelin using radiolabeled monoclonal antibodies showed good localization and specificity for relevant tumors. So far, anti-mesothelin antibody-drug conjugates have been successfully used to treat mesothelin-expressing solid tumors, including ovarian cancer, pancreatic cancer, and malignant mesothelioma; and mesothelin targets chimeric antigen receptor (CAR) T cell therapy also showed significant antitumor effects. Therefore, targeted therapy and immunotherapy against mesothelin show promising application prospects.